Credit: Qure.ai
Indian startup Qure.ai last week announced the company s separate partnerships to have its AI-powered software used for screening various diseases such as COVID-19 and tuberculosis.
It teamed up with Fujifilm Corporation to equip the brand s smart radiograph system with artificial intelligence, while it also partnered with AstraZeneca Malaysia to use its AI diagnostics software to support the early detection of lung cancer in Malaysia.
WHY IT MATTERS
Qure.ai brings qXR, its deep-learning AI technology software, to Fujifilm s portable X-ray FDR Xair system, enabling the device to analyse radiographs and detect abnormal findings within seconds. The integration of the AI software into the device was made possible through an image processing box called Expansion Unit EX-Mobile.
HKSTP, AstraZeneca push Hong Kong as biomedical innovation hub
HKSTP, AstraZeneca push Hong Kong as biomedical innovation hub 16 February 2021 | News
Photo Credit: HKSTP
AstraZeneca and the Hong Kong Science and Technology Parks Corporation (HKSTP) have launched a co-incubation programme to support biomedical startups in their mission to develop integrated oncology solutions to accelerate innovation in oncology, foster local biomedical technologies and enhance Hong Kong’s status as a leading biomedical innovation hub.
In the last decade, malignant cancerous tumours have been the number one cause of death among all diseases in Hong Kong. Today’s cancer treatment solutions, physical check-ups, diagnosis, treatment, follow-up and rehabilitation, are all interrelated. Improvements in either aspect of the patient journey will create huge opportunities to drive better treatment outcomes.